Home Page

CAMBRIDGE, Mass., June 19, 2018 (GLOBE NEWSWIRE) -- Biogen (Nasdaq:BIIB) today announced it will host a live webcast providing an overview of its efforts targeting acute ischemic stroke on Thursday, June 28, 2018.  The live webcast will be from 8:00-9:00 a.m. ET with Michael Ehlers, M.D., Ph.D., executive vice president, Research and Development, and Chirfi Guindo, executive vice president, head of Global Marketing, Market Access and Customer Innovation. To access the live webcast, please go to the investors section of Biogen’s website at www.biogen.com/investors.  Following the live webcast, an archived version of the call will be available on the website.

About Biogen
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp, and today has the leading portfolio of medicines to treat multiple sclerosis; has introduced the first and only approved treatment for spinal muscular atrophy; and is focused on advancing neuroscience research programs in Alzheimer’s disease and dementia, multiple sclerosis and neuroimmunology, movement disorders, neuromuscular disorders, pain, ophthalmology, neuropsychiatry, and acute neurology. Biogen also manufactures and commercializes biosimilars of advanced biologics.

We routinely post information that may be important to investors on our website at www.biogen.com. To learn more, please visit www.biogen.com and follow us on social media – Twitter, LinkedIn, Facebook, YouTube.

Contact:
Karen Jewell
Investor Relations
Biogen
781.464.2442